HopeTalk

A Video Podcast by HopeAI

At the Frontiers
of AIin Drug Development

Artificial Intelligence is reshaping how life-saving medicines are discovered, developed, and delivered to patients. From accelerating clinical trials to uncovering new therapeutic possibilities, AI is helping scientists, clinicians, and innovators bring hope where it's needed most.

Hosted by the HopeAI team, HopeTalk™ brings together pioneers across biopharma, healthcare technology, venture investment, and patient advocacy to explore how intelligent systems are transforming the path from data to cures.

Through candid conversations with those driving the change—researchers at the bench, leaders in pharma, visionary entrepreneurs, and patients experiencing the impact firsthand—we uncover the real stories, breakthroughs, and human promise behind the convergence of AI and drug development.

Because when AI meets human perseverance, every discovery moves us closer to hope realized.

Recent

Episode Two
Why AI Is Finally Ready to Change Clinical Trial Design — and Why It Matters Now

In this episode of HopeTalk, we speak with Dr. Hiroshi Tamada, Chief Medical Officer at Remiges Ventures, about why clinical trial design has become the true inflection point in drug development.

Drawing on experience across medicine, pharma, biotech, and venture capital, Dr. Tamada explains why trial design decisions are uniquely high-stakes—made under deep uncertainty and often irreversible, especially for small biotechs.

We explore how AI is beginning to change clinical decision-making through three use cases: sample size design and re-estimation, AI-enabled statistical innovation including covariate adjustment, and synthetic individual patient data.

Finally, we address the regulatory reality—how FDA is approaching AI today—and close with practical guidance on using AI responsibly without sacrificing scientific rigor or value.

Episode One
In Conversation with Dr. Tanja Obradovic

In our first episode, we sit down with Dr. Tanja Obradovic, Scientific Advisor at HopeAI and a global leader in oncology clinical development.

Dr. Obradovic played a key role in the development of KEYTRUDA® (pembrolizumab)—one of the most impactful cancer immunotherapies to date.

Together, we explore why decision-making—not paperwork—drives speed, cost, and outcomes in clinical development, and what responsible AI adoption truly requires.